Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

SPARXS High throughput development platform for oligonucleotide aptamers

Coordinator
Technische Universiteit Delft, Netherlands
Runs
1 March 2024 to 31 August 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101158219

What the project is doing

In the project's own words, from its summary on CORDIS.

The binding kinetics of an affinity probethe speed and duration with which it attaches to a target moleculemust be precisely tuned for numerous applications in therapeutics, super-resolution microscopy, and biochemical assays. The current methods of development lack the capability to specify these binding kinetics during probe design, resulting in the potential for effective drugs and relevant biological properties to remain undiscovered.

Here, I introduce a game-changing solution: Single-molecule Parallel Analysis for Rapid eXploration of Sequence space (SPARXS). SPARXS harnesses the power of single-molecule observations and subsequent high-throughput sequencing to simultaneously reveal the binding kinetics and sequences of millions of aptamers (affinity probes composed of nucleic acids). This process enables the tailored design of probes with the desired binding behavior for various applications.

This technology originated from my ERC Consolidator Grant project as a research tool, and its application can fulfill multiple practical demands. As SPARXS provides a particularly excellent fit for aptamer development, I have decided to enhance the platform with aptamer-specific features. Furthermore, I will conduct market research to understand the specific demands of users seeking defined-kinetic probes, which will facilitate commercialization of SPARXS-based aptamer design upon completion of the project.

In summary, SPARXS signifies a disruptive advancement in aptamer development and will revolutionize affinity probe design across the biotech industry. With minimal adaptations to the core technology, I anticipate a high potential for swift commercialization as a dedicated development platform.

Topics

Who is involved

OrganisationCityCountryRole
Technische Universiteit DelftDelftNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI